Featured Press Releases

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

ProJenX announces the formation of its Clinical Advisory Board

ProJenX announces the formation of its Clinical Advisory Board

  • 27 Aug 2024

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies...

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

  • CollPlant
  • 24 Feb 2026
With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

  • Bruker Corporation
  • 24 Feb 2026
SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

  • Clarity Pharmaceuticals
  • 23 Feb 2026
PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

  • PureTech Health plc
  • 20 Feb 2026
ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

  • Merck & Co., Inc.
  • 19 Feb 2026
Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.